Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96SL4
UPID:
GPX7_HUMAN
Alternative names:
CL683
Alternative UPACC:
Q96SL4; O95337; Q5T501
Background:
Glutathione peroxidase 7 (GPX7), also known as CL683, plays a crucial role in protecting esophageal epithelia from oxidative stress. It achieves this by neutralizing hydrogen peroxide and suppressing reactive oxygen species (ROS) induced by acidic bile acid. This action is vital in preventing oxidative DNA damage and double-strand breaks, safeguarding cellular integrity.
Therapeutic significance:
GPX7's dysfunction is linked to Barrett esophagus, a condition where esophageal squamous epithelium transforms into a columnar and intestinal-type epithelium, increasing esophageal adenocarcinoma risk. Understanding GPX7's role could open doors to potential therapeutic strategies for Barrett esophagus by targeting the oxidative stress pathway.